On February 4, 2026, Citigroup upgraded Bio-Techne’s stock to a Buy rating and increased its 12-month price target from 70 to 80. The upgrade reflects Citigroup’s expectation of accelerating end-market demand for the company’s research reagents and diagnostics platforms. Analysts cited improving momentum in large pharma partnerships and expanding adoption of spatial biology assays as key drivers for revising both near-term earnings estimates and longer-term revenue projections.

Bio-Techne reported second-quarter revenue of 295.9 million, flat year-over-year on both reported and organic bases. GAAP EPS rose to 0.24 from 0.22, while adjusted EPS increased to 0.46, up from 0.42 in the prior period. Adjusted operating margin expanded by 100 basis points to 31.1%, driven by productivity initiatives and the divestiture of its Exosome Diagnostics business. The Protein Sciences segment delivered 2% net sales growth to 215.1 million despite a 1% organic decline, and segment margin remained above 39%. The Diagnostics and Spatial Biology unit generated 81.2 million in net sales, with organic growth of 3%, and improved operating margin to 10.4%.

Bio-Techne’s board declared a quarterly dividend of 0.08 per share, payable February 27, 2026, to shareholders of record on February 16, 2026. This marks the company’s eighth consecutive quarterly distribution and reflects confidence in its free cash flow generation. In fiscal 2025, Bio-Techne generated over 1.2 billion in net sales and maintained a robust balance sheet with approximately 3,100 employees supporting global operations.